Eli Lilly has unveiled plans to expand its long-standing partnership with Purdue University, with the drugmaker investing up ...

AbbVie’s Emrelis (telisotuzumab vedotin-tllv) has been granted accelerated approval by the US Food and Drug Administration ...

New McKinsey and Gartner data show that organisations who regularly reset strategy can outperform peers by up to 60%. In fast ...

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with ...

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

Cytokinetics has shared positive top-line results from a late-stage study of its investigational oral cardiac myosin ...

Eli Lilly has announced that its Zepbound (tirzepatide) was superior to Novo Nordisk’s Wegovy (semaglutide) across all weight ...

Pharma marketers are embracing chat-based tools to engage HCPs and patients faster, simplify PI sharing, and gain real-time ...

We can’t talk about challenges to women’s reproductive health without acknowledging that we’re living in unprecedented times, ...

Roche’s Perjeta (pertuzumab)-based regimen has demonstrated sustained survival benefits in patients with early-stage breast ...

Johnson & Johnson (J&J) has announced that its bladder cancer therapy Balversa (erdafitinib) has been accepted by the ...

The phase 3 GLISTEN trial has been evaluating the candidate in adults with PBC and cholestatic pruritus, or relentless itch, ...